Sapacitabine: Phase II started

Cyclacel began an open-label, dose-escalating Phase II trial in about 60 patients. The company licensed exclusive rights to sapacitabine from Daiichi Sankyo in 2003 (see BioCentury, Dec. 8, 2003). ...